Every day, the sun rises on Wall Street, and a plethora of professional analysts wake to issue new opinions on stocks. Here at the Fool, we use our "This Just In" column to examine some of these picks -- and the track record of the firms behind them -- so individuals can make better investing decisions.
In addition to following professional analysts, anyone can use Motley Fool CAPS to monitor the collective opinions of more than 110,000 members, many of whom demonstrate better investing insight than published analysts do.
Enough top-performing CAPS members have turned bullish on Celgene
While CAPS members have fingered diversified conglomerates like Procter & Gamble
Celgene has topped a list of other biotechs, including Immucor
To see what the highest-rated CAPS members are saying now about Celgene -- as well as other winning stocks they are picking -- head on over to CAPS and have a look. The community research and resources in CAPS are totally free, unlike analyst opinions reserved for paying clients.
Always looking ahead, the Motley Fool Rule Breakers service has recommended several biotechs with blockbuster potential. To see what other rule-breaking stocks David Gardner and his team are picking today, take a free 30-day trial.
Fool contributor Dave Mock recently upgraded his office with water-conserving foliage. He owns shares of Johnson & Johnson and is the author of The Qualcomm Equation. Johnson & Johnson is an Income Investor pick. BioMarin Pharmaceutical is a Rule Breakers recommendation. The Fool's disclosure policy lives life on the edge.